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Abstract
Breast cancer is the most prevalent cancer type among women. Despite recent progress 
in early detection and therapeutic strategies, the rate of mortality is increasing. Anti-
estrogens or aromatase inhibitors are preferred to treat the women diagnosed with estro-
gen-receptor (ER) positive tumors. However, breast tumors usually show intra-tumoral 
heterogeneity with ER-positive and -negative cells. The advanced breast cancer cells lose 
the estrogen responsiveness and become aggressive by developing new strategies for 
rapid proliferation such as mutations in cell cycle machinery. New promising drugs are 
still being investigating against these types of tumors especially to overcome acquired 
resistance against chemotherapeutic drugs; however, a successful treatment for meta-
static tumors is still unclear. Flavonoids, with various pharmacological activities, are 
plant or fungus secondary metabolites present in human diet. In plants, beside their role 
in pigmentation, they may also act as messengers, regulators and cell cycle inhibitors. 
Therefore, they are being tested in ovarian, cervical as well as breast cancer. Due to the 
positive correlation between flavonoids-rich diet and lower risk of cancer, flavonoids 
are referred as chemopreventive agents. The current chapter emphasizes the therapeutic 
potential of flavonoids and their synthetic analogues as anti-cancer agents in breast can-
cer providing new insights into the molecular mechanisms.
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1. Introduction
The use of natural and dietary agents for cancer chemoprevention and therapy received 
attention for their health benefits. As consumption of fruits or vegetables has been associated 
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with a reduced risk of human cancers especially breast cancer [1], dietary flavonoids, found 
particularly in these alimentary groups with more than 5000 polyphenolic compounds, 
have been identified as potential cancer-preventive components [2, 3]. Polyphenols can be 
divided into ten different classes based on their chemical structure [4]. Flavonoids, phenolic 
acids, stilbenes, and lignans are the most abundant polyphenols in plants. Polyphenols, 
mainly flavonoids, possess a number of functions including pollination, pollen tube 
growth, resorption of minerals, and tolerance to abiotic stress [5]. Flavonoids represented 
greater attention with the decreased incidence of cancer and cardiovascular diseases in 
Mediterranean population, which was associated with vegetables, fruits, and red wine con-
sumption. Therefore, they have been under investigation for their therapeutic significance 
in the protection of human health for decades. Flavonoids are one of the common compo-
nents in the human diet and generally are present as O-glycosides with sugars bound at 
C3 position [6].
Breast cancer is the leading cause of cancer death among women worldwide. Despite the 
presence of new promising advances in therapeutics, the breast cancer mortality rate is still 
increasing. Recent reports suggest that breast cancer prognosis is lower in countries consum-
ing a healthy, plant-based diet [7]. The possible cause to this scenario has been suggested 
as flavonoids in fruits and vegetables. Epidemiologic investigations showed that flavonoids 
exhibit important effects on cancer chemoprevention and chemotherapy. They have been 
shown to interact with different genes and enzymes including those playing role in antipro-
liferation, cell cycle arrest, apoptosis, angiogenesis, and multidrug resistance. Therefore, this 
chapter focuses on the chemopreventive and chemotherapeutical roles of flavonoids in the 
treatment of breast cancer [6].
2. Structure, classification and metabolism in humans
The chemical structure of flavonoids is based on a C15 skeleton with a chromane ring bearing 
a second aromatic ring B in position 2, 3, or 4 (Figure 1).
 Figure 1. Basic flavonoid structure [8].
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Flavonoids are subdivided into different groups based on the nature of C3 element: flavones, 
flavonols, flavanones, flavanols, anthocyanins, and isoflavones (Figure 2).
Flavonoids participate light-dependent phase of photosynthesis [9], and they catalyze elec-
tron transport. They have been shown to be synthesized from phenylalanine and tyrosine, the 
aromatic amino acids, with acetates [10]. First, aromatic amino acids are converted to cinnamic 
acid and parahydroxycinnamic acid, respectively, by phenylalanine and tyrosine ammonia 
lyase enzymes [11]. Then, parahydroxycinnamic acid accumulates with acetate units to give 
rise to cinnamoyl, which is the derivative of caffeic acid and chlorogenic acid. Cinnamoyl, 
then, is converted to ortho-hydroxyacetophenone with a benzaldehyde derivative generat-
ing flavonones. If ortho-hydroxyacetophenone condenses with a benzoic acid derivative, 
flavones are formed. Anthocyanins are naturally occurring glycosides of flavylium (2-phenyl-
1-benzopyrylium) ions substituted by hydroxyl and methoxyl groups. Biotransformation of 
flavonoids occurs in the gut and various secondary metabolites are produced as well such as 
phenolic acids, lignins, lignans, and stilbenes [11].
Flavonoids, mainly flavanols and quercetin glucosides, are absorbed from the small intestine, 
while quercetin, quercetin galactoside, and many others are not [12]. Those absorbed by the 
intestine have been shown to be transported through membrane and use both ATP-dependent 
pumps and ATP-independent transporters [13]. Following absorption, they are metabolized 
via microbial catabolism and conjugated in the liver and enterocytes [14]. Depending on the 
subclass, only 5–10% of the amount consumed was shown to be absorbed in the intestine; 
the rest excreted through the colon where they are further metabolized. The absorbed part 
in the duodenum is found as methylated, sulfate-conjugated, glucuronide-conjugated, or 
glycine-conjugated forms [15]. Firstly, in 1992, Hertog et al. measured the content of flavo-
noids in different fruits, vegetables, and wine. Their findings indicated that mostly quercetin, 
kaempferol, myricetin, apigenin, and luteolin are found as flavonoid subclasses in the diet. 
They also suggested that the mean daily intake of flavonoids was higher than the antioxi-
dants β-carotene, vitamin E, and vitamin C [16]. However, the measurement of daily flavo-
noid intake is difficult to estimate since a standardized method is lacking [17]. Flavonoids, 
except catechins, exist in nature as glycosides. Following flavonoid intake, the glucosides are 
 Figure 2. Subclasses of flavonoids (PubChem).
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cleaved and glucuronated. Glucuronides can be metabolized, released, or stored as aglycones 
by glucuronidases in a tissue-specific manner [18]. Although the glycosylation of flavonoids 
has been suggested important for their absorption, the non-glycosylated form of catechin 
intake has been shown relatively efficient [19]. Flavonoids, especially flavanols, flavonols, and 
anthocyanins, are relatively abundant in human diet and are shown to play role in cancer, 
cardiovascular, and neurodegenerative disease disorder prevention [20].
3. Flavonoid-rich food and medicinal plants
The plant extracts have been used as folk remedies against various health problems, includ-
ing metabolic diseases, cancer, and neurodegenerative disorders. According to in vitro and in 
vivo studies, a number of plant species have antiproliferative and antitumoral role in breast 
cancer pathogenesis. In addition, plants which have higher amount of flavonoids are accepted 
as chemopreventive agents. According to the United States Department of Agriculture 
(USDA) database, the six subclasses of flavonoids are listed for 506 food items. According to 
the database, flavonols (quercetin, kaempferol, myricetin, isorhamnetin), flavones (luteolin, 
apigenin), flavanones (hesperetin, naringenin, eriodictyol), flavan-3-ols ((+)-catechin, (+)-gal-
locatechin (GC), (−)-epicatechin (EC), (−)-epigallocatechin (EGC), (−)-epicatechin 3-gallate, 
(−)-epigallocatechin 3-gallate, theaflavin, theaflavin 3-gallate, theaflavin 3′-gallate, theaflavin 
3,3′ digallate, thearubigins), anthocyanidins (cyanidin, delphinidin, malvidin, pelargonidin, 
peonidin, petunidin), and isoflavones (genistein, daidzein, glycitein) are listed.
Generally, these dietary compounds are known with their antioxidant, anti-inflammatory, 
and anticarcinogenic effects. According to the Seven Countries Study report, the average 
consumption of quercetin, kaempferol, myricetin, luteolin, and apigenin in composite food 
samples have ranged from 6 mg/day in Finland to 64 mg/day in Japan, with intermedi-
ate intakes in the United States (13 mg/day), Italy (27 mg/day), and the Netherlands (33 
mg/day). In a similar study report, average flavonoid intake in Hungarian population was 
lower compared to Dutch, Danish, and Finnish citizens. The intake of five flavonoids in 17 
different diets was estimated. When diet types were compared to each other according to 
flavonoid consumption ratio, it was shown that South African diet is the lowest flavonoid 
consumed diet type as 1–9 mg/day consumption. In contrary, Scandinavian diet in correla-
tion with population-based study outcomes was the higher flavonoid intake diet type (75–81 
mg/day).
In addition dietary origin of the flavonoids varied between countries. While tea is the main 
dietary source of flavanoids in Japan by 95% and the Netherlands by 64%, alcoholic bever-
ages such as famous resveratrol based popularity of red wine and beer in Italy by 46%. The 
vegetables and fruits are the most common dietary sources of Scandinavian countries such 
as Finland by 100%. Similar ratio was also observed in the United States by 80%. In Australia, 
tea is the major source of flavonoid, and flavan-3-ols are 75% of whole intake. Therefore, it is 
important to evaluate the chemopreventive and chemotherapeutic potential of flavonoids in 
breast cancer disease.
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In this section, it is aimed to discuss potential molecular mechanism of above-listed flava-
noids in breast cancer studies.
3.1. Flavanols
3.1.1. Quercetin
Quercetin is a natural dietary flavonoid which exerts antioxidant, anti-inflammatory and 
anticancer properties. Quercetin is found in barks of many plants, fruits, and vegetables. It is 
one of the well-established grape polyphenols like other members, resveratrol, naringenin, 
and catechin, can exert antitumoral, antioxidant, anti-angiogenic properties and modify 
selectively estrogen-receptor (ER). According to a recent study, it is found that quercetin at 
IC50 value (37 μM) modulated Twist and p38 MAPK signaling, which lead to apoptosis in 
MCF-7 and MDA-MB-231 breast cancer cells [21]. In addition it is well documented that quer-
cetin exerts its therapeutic effect through modulating different cellular targets. According 
to the previous study, it was shown that quercetin induced p21 CDK inhibitor with a con-
comitant decrease of phosphorylation of retinoblastoma (Rb), which inhibits the G1/S cell 
cycle progression by trapping E2F1. A low dose of quercetin induced mild DNA damage 
and Chk2 activation, which is the main regulator of p21 expression by quercetin. In addi-
tion, quercetin downregulated the cyclin B1 and CDK1, essential components of G2/M cell 
cycle progression. Inhibition of the recruitment of key transcription factor NF-Y to cyclin 
B1 gene promoter by quercetin led to transcriptional inhibition SKBR3, MDA-MB-453, and 
MDA-MB-231 cells [22, 23].
Similar to previous findings, MCF-7 breast cancer cells were exposed to the increasing con-
centrations of quercetin; consequently, cell viability ratios were decreased, and apoptosis was 
triggered. Following exposure of cells to moderate cytotoxic dose of quercetin for 48 h, cells 
undergo apoptosis due to activation of caspases. In addition, quercetin mediates the disrup-
tion of Bcl-2/Bax ratio in MCF-7 cells [24].
3.1.2. Kaempferol
A dietary flavonoid, kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-
4-one), is found in edible plants such as kale, beans, endive, tea, broccoli, cabbage, tomato, 
and grapes, is commonly used in traditional medicine (e.g., Ginkgo biloba, Tilia spp., Equisetum 
spp., Moringa oleifera, Sophora japonica, and propolis) has been reported as antimicrobial, 
anticancer, antioxidant, neuroprotective, cardioprotective, and antiallergic activity [25]. 
Kaempferol leads to anti-angiogenic effect via reducing vascular endothelial growth factor 
(VEGF) expression in ovarian cancer cells [26]. Moreover, it enhanced the effect of cisplatin in 
ovarian cancer and induced cell cycle arrest and apoptosis by modulating Bcl-2-Bax expres-
sion. In vitro studies about kaempferol on breast cancer cases, time-dependent exposure of 
cells to flavonoid (50 μM) induced G2/M arrest via inhibiting CDK1; cyclin A, and cyclin B and 
induced apoptosis by p53 phosphorylation in MDA-MB-453 breast cancer cell [27]. Although 
kaempferol treatment significantly induced cell viability loss in MCF-7 cells, no significant 
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effect has been reported in MDA-MB-231 breast cancer cells or HC-11 mammary epithelial 
cells. Kaempferol-induced ERK activated apoptotic cell death and reactive oxygen species 
(ROS) generation and N-acetyl cysteine (NAC) co-treatment prevented kaempferol-mediated 
poly (ADP-ribose) polymerase (PARP) cleavage in MCF-7 breast cancer cells [28]. Kaempferol 
could be extracted from Murraya koenigii leaf, which was reported to induce caspase-3-de-
pendent apoptotic cell death and inhibited endogenous 26S proteasomal enzyme activity in 
MDA-MB-231 breast cancer cells. Moreover, dose-dependent kaempferol treatment reduced 
the tumor growth through inhibiting the expression of angiogenic and antiapoptotic genes 
in breast cancer xenografts [29]. In vivo breast cancer xenograft mice models, kaempferol-
mediated anticancer effect reported via downregulation of IRS-1, pAkt, pMEK1/2, and ERK 
gene expression and decreased the tumor growth and volume. In addition, kaempferol treat-
ment prevents breast cancer invasion and metastasis in MDA-MB-231 breast cancer cells due 
to reduction in MMP-2 and MMP-9 expressions, suppression of transcription factor activa-
tor protein-1 (AP-1) and MAPK signaling [30]. Lymphangiogenesis, a new lymphatic vessels 
formation process, is a major step in spreading of tumor cells. Lymphangiogenesis inhibitors 
might be focused as an important drug target strategy in breast cancer cells. A VEGFR2/3 
kinase inhibitor, kaempferol, inhibited mammalian lymphangiogenesis in metastatic breast 
cancer xenograft models [31].
3.1.3. Myricetin
The use of plant derivatives, which exert biological functions, has gained importance in recent 
years. Myricetin (3,5,7,3′,4′,5′-hexahydroxyflavone cannabiscetin) is a natural flavonol, which 
has a unique hydrophobic chemical structure found in different varieties of fruits, vegetables, 
tea, berries, etc. [32]. The dietary intake of myricetin from our foods is about 0.98–1.1 mg 
per day, which is quite higher than some other flavonols [33]. Recent studies showed that 
myricetin is an antioxidant and it possesses cytoprotective, anticarcinogenic, antiviral, and 
antimicrobial effects [34].
3.1.4. Isorhamnetin
Isorhamnetin is one of the important flavanols found in G. biloba leaf extracts. Isorhamnetin is 
also found in parsley, and thereby it is a common dietary flavonoid as the metabolite of quer-
cetin. Generally, it is well known as antagonist of peroxisome proliferator-activated receptor 
γ (PPARγ), which inhibits adipocyte differentiation induced by the PPARγ agonist rosigli-
tazone [35]. Isorhamnetin is a naturally occurring compound in fruits and vegetables; recent 
study showed that isorhamnetin could significantly inhibit the invasion of MDA-MB-231 cells 
by downregulating matrix metalloproteinases (MMP-2 and MMP-9) through inhibiting p38 
MAPK and STAT3 [36]. Similar results were also obtained in another study, which showed 
that isorhamnetin inhibited cell proliferation and led to apoptosis. In addition, isorhamnetin 
was found effective on Akt/mTOR/MAPKs signaling axis. It was established that isorham-
netin-induced autophagy can be reversed by the co-treatment of 3-methyl-adenine in lung 
cancer cells. The results indicated that isorhamnetin exerts antitumor effect in breast cancer 
through targeting multiple molecular targets [37].
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3.1.5. Silymarin
In recent years, chemopreventive potential of fruits, vegetables, and medicinal herbs such as 
tea due to ingredients rich in phytochemicals that act as an antioxidant become an impor-
tant agent. One of the polyphenolic flavonoids silymarin that is isolated from milk thistle 
(Silybum marianum (L.) Gaertn) has been shown for its antioxidant action against liver toxicity 
[38]. Recently, studies reported the anticarcinogenic effect of silymarin in several mouse skin 
tumorigenic samples and cervical, prostate, liver, and breast cancers. The molecular machin-
ery of silymarin was more frequently shown in the treatment of human umbilical vein endo-
thelial cells (HUVECs), and downregulation of survivin, Akt, and nuclear factor (NF)-κB was 
observed [39]. Beside cell growth and proliferation inhibition, silymarin was demonstrated 
as an inhibitor of MMPs and in vitro angiogenesis. Silymarin induced liver cancer prevention 
due to membrane stabilizing antioxidant effect through acting on tumor necrosis factor alpha 
(TNF-α) expression in hepatocellular carcinoma cells [40]. Moreover, VEGF secretion sup-
pression instead of normal epithelial cells, in prostate and breast cancer epithelial cells, has 
also been reported in Ref. [41]. In MCF-7 breast cancer cells, silymarin treatment inhibited cell 
growth via upregulating ERB. However, ER alpha (ERα) downregulation is reported to be an 
important key player in drug-induced autophagy and apoptosis in MCF-7 breast cancer cells 
via Akt/mTOR/ERK signaling pathway [42].
3.2. Flavanes
3.2.1. Luteolin
Luteolin (3′,4′,5,7-tetrahydroxyflavone) which belongs to flavonoids is a heat-stable and non-
toxic compound. It is found in vegetables and fruits such as celery, parsley, broccoli, onion 
leaves, carrots, peppers, cabbages, apple skins, and mignonette and chrysanthemum flowers. 
As well as other flavanoids, cardiovascular protection, immune system stimulation, antioxi-
dant, anti-inflammatory, and anticarcinogenesis capacities of luteolin have been shown in pre-
vious studies [43]. Luteolin exerts its molecular effect via inducing different signaling routes 
in dose-dependent manner. According to previous studies, it is well documented that lutein 
is both pro- and antioxidant compound. The pro-oxidant activity of flavonoids may be related 
to their ability to undergo autoxidation catalyzed by transition metals to produce superoxide 
anions [44]. Due to structural differences including bioactive phenolic ring, prooxidant status 
of luteolin may increase the cytotoxicity in cells. Luteolin is important in ER-expressing cells. 
It was shown that luteolin at low concentrations is an antiestrogenic agent and reduces cell 
proliferation. In addition, luteolin may inhibit aromatase whose function is to catalyze the 
production of estrogens [44]. A recent study indicated that luteolin downregulates ER and 
thus caused the degeneration of ER protein. Because the etiology of breast cancer is strongly 
correlated with nuclear hormone receptor activity, the consumption of luteolin in diet may 
reduce risk through regulation of estrogen-induced cellular effects. In vitro and in vivo stud-
ies showed that luteolin prevented estrogen-induced cell proliferation. It was shown that 
luteolin impaired estrogen signaling pathway (ESP) in MCF-7 cells by microarray analysis 
[45]. Luteolin altered cell cycle regulation signaling targets, including CCNA2, PLK1, PCNA, 
and CDKN1A. This result was considered as the final consequence of ESP modulation, which 
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suppresses cell proliferation in breast cancer cells. A previous study showed that luteolin 
(5 μM) could be utilized as a chemosensitizing mechanism to target the expression level of 
cyclin E2 and to overcome tamoxifen resistance in breast cancer patients. In vivo studies also 
showed that luteolin may exert its effect via modulating miRNA expressions such as miR-34a 
and miR-181a which bidirectionally reduced notch and suppressed invasion mechanism [46].
3.2.2. Apigenin
Apigenin is known as the phytoestrogen, used in postmenapausal symptom treatment, and 
presented in various plant species. Although it is a nontoxic and non-mutagenic plant deriva-
tive, it exerts antitumoral activity in different types of cancers and induces oxidative stress 
in breast cancer cells [47]. However, there are contradictory reports showing that apigenin 
might stimulate cell proliferation in ERα-positive MCF-7 and T47D cells, but not effective in 
ERα-negative MDA-MB-435 breast cancer cells [48]. The molecular mechanism of apigenin- 
induced apoptotic cell death was caspase-dependent, mitochondria [49] and NF-κB, STAT 
signaling-mediated [50]. Moreover, apigenin inhibited cell growth, metastasis, and invasion 
in breast cancer cells via acting on PI3K/Akt signaling and beta 4 integrin in MDA-MB-231 
breast cancer cells [51].
3.3. Flavanones
It was shown that flavanone-rich diet mediated 0.1 –100 μM physiologically achievable 
concentration in the plasma. One of the mostly known flavanones is naringenin, which is 
especially abundant in the Mediterranean diet, rich for consumption of grapes, tomato, and 
citrus. Naringenin was shown with anticancerous effect in various cancer cells. According to 
in vitro studies, it was shown that naringenin modulated NF-κB to induce apoptosis in the 
cells. Naringenin was effective in MCF-7 ERα+/ERβ + cell line, but not in ER-independent 
SKBR-3 (ERα−/ERβ−) cell line [52–55]. Thymus vulgaris ethanol extraction originated in nar-
ingenin induced cell cycle arrest at S and G2/M phases, which led to apoptotic induction in 
HTB26 and HTB132 breast cancer cells [52]. The apoptotic efficiency of naringenin was found 
due to alteration of different cell cycles and apoptosis-related genes such as cyclin-dependent 
kinases and Bcl-2 family members. Naringenin may activate T cells to induce antitumoral 
activity in mice and lead to increased interferon (IFN)-γ and interleukin (IL)-2 expressing T 
cell population [54, 56]. Naringenin promotes the therapeutic effect of tamoxifen in breast 
cancer cells [57, 58]. Thus, naringenin might promote the potential therapy outcomes and 
good prognosis in breast cancer cases.
Similar to naringenin, eriodictyol has promising therapeutic effects in cancer cells. Eriodictyol, 
a flavanone, activated Nrf2 and induced phase II proteins to exert its antioxidant effects 
[59, 60]. However, there are less studies to evaluate the molecular mechanism of eriodictyol 
compared to naringenin.
Hesperetin is also a promising flavanone and induced cell cycle arrest at G1 phase. According 
to the previous study, hesperetin regulated CDK4 and p21 (Cip1) in MCF-7 cells and led to 
block of cell cycle. Hesperetin is also known with its apoptotic effect in breast cancer cells 
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without effecting normal mammary epithelial cells. It was shown that hesperetin induced 
apoptosis in dose- and time-dependent manner in MCF-7 cells through triggering ROS gen-
eration. Pretreatment of NAC prevented hesperetin-induced apoptosis, which is under con-
trol of ASK1/JNK pathway. In addition, hesperetin also induced apoptosis in triple-negative 
breast cancer MDA-MB-231 cells via intrinsic apoptotic pathway [53, 61–64]. In the light of 
previous findings, both naringenin and hesperetin are known as promising therapeutic can-
didates in breast cancer due to their sensitizing effect of HER2-positive breast cancer cells.
3.4. Flavan-3-ols
The most important member of flavan-3-ols (catechins) is abundantly present in green and 
black tea, red wine and chocolate. Catechins, which are generally found in green tea, com-
prise epigallocatechin gallate (EGCG), epicatechin (EC), gallocatechin (GC), epigallocatechin 
(EGC), catechin gallate (CG), epicatechin gallate (ECG), gallocatechin gallate (GCG), and cat-
echin (C). Although green tea is a favorable catechin source, it is required to design more 
bioavailable structures to treat various cancer types, including breast cancer. The detailed 
investigation for EGCG was established in different studies. According to xenograft model 
studies, EGCG with tamoxifen has potential in ER-negative breast cancer models. The MDA-
MB-231-mediated tumor volume was decreased following 25 mg/kg treatment of EGCG and/
or EGCG + tamoxifen in athymic nude female mice model [65–68]. The potentiation of green 
tea catechins is generally acted on mTOR and EGFR pathways. Similar to these findings, stud-
ies indicated that EGCG produces anticancer effect by modulating the activity of MAPKs, IGF/
IGF-1 receptor, Akt, NF-κB, and HIF-1α [69–73]. Although catechins have multiple molecular 
targets in the cells, it is required to improve their structural properties to achieve powerful 
treatment results.
3.5. Anthocyanins
Anthocyanins confer the bright red, blue, and purple colors to plants such as berries, grapes, 
and apples. Anthocyanidins lack the sugar component of the anthocyanin [74]. Six anthocy-
anidins occurred most commonly in nature are pelargonidin, cyanidin, peonidin, delphini-
din, petunidin, and malvidin. It has been suggested that the consumption of cyanidin lowers 
the risk of cardiovascular disease, diabetes, and cancer due to the antioxidant and anti-inflam-
matory activities [75]. The phenolic structure is responsible for the antioxidant activity such as 
the ability to scavenge superoxide (O
2
·−), singlet oxygen (‘O
2
), peroxide (ROO−), hydrogen per-
oxide (H
2
O
2
), and hydroxyl radical (OH·), members of ROS [76], in in vitro cell lines including 
colon, liver, and breast cancer cells [77].
3.5.1. Cyanidin
The anticancer effect of cyanidin-rich extracts of different plant has been shown in MCF-7 ERα 
(+), MDA-MB-231 ER α (−), and MDA-MB-453 ER α (−) breast cancer cell lines. Moreover, apop-
totic induction in MDA-MB-453 cells through the intrinsic pathway of apoptosis by activating 
caspase cascade, cleaving poly (ADP-ribose) polymerase (PARP), depolarizing  mitochondrial 
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membrane potential, and releasing cytochrome C has been shown [78]. In addition, in the 
same study, 100 mg/kg/day oral administration of cyanidin has been shown to reduce tumor 
growth and angiogenesis by affecting the expression of angiogenic factors MMP-9, MMP-
2, and cell/extracellular matrix (ECM) interaction in nude mice bearing MDA-MB-453 cell 
xenografts [78]. Furthermore, inhibition of proliferation and cell cycle arrest were induced in 
MCF-7 human breast cancer cells after the treatment of bilberry extract, which contains high 
amount of cyanidin [79]. The same study also compared the effect of cyanidin with a well-
known antioxidant Trolox, a vitamin E analog, and showed that cyaniding induced apoptosis 
and cell cycle arrest as much as Trolox [80]. In another study, pycnogenol, derived from pine 
bark, which contains high amounts of procyanidins, has been shown to induce cell death 
in breast cancer cells (derived from human fibrocystic mammary tissue) but not in normal 
human mammary MCF-10A cells [81].
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% cases of breast 
cancer. Therefore, HER2-targeted therapies have been evaluated in recent years. In Liu et 
al.’s [82] study, cyanidin-3-glucoside, extracted from black rice, inhibited phospho-HER2 and 
phospho-AKT and induced apoptosis both in vitro and in vivo HER2-positive breast cancer 
cells and tissues. Another study also revealed that anthocyanidin-rich extracts from berries 
and grapes have been shown to exhibit proapoptotic effects in multiple cell types in vitro [83]. 
They induce apoptosis through both intrinsic (mitochondrial) and extrinsic (FAS) pathways.
3.5.2. Delphinidin
Delphinidin is a member of anthocyanins mainly found in pomegranate extract and found 
in many dietary supplements as complementary cancer medicine. A recent study showed 
that delphinidin treatment inhibited cell proliferation and induced apoptosis in ER-positive, 
triple-negative, and HER2-overexpressing breast cancer cell lines without any toxic effect in 
normal breast epithelial cells [84]. In addition, the same study also indicated that MAPK sig-
naling was inhibited in both triple-negative and ER-negative breast cancer cells but not in 
MCF-10A normal epithelial cells.
Breast cancer cells overexpressing p65, the unit of NF-κB responsible from cell survival and 
proliferation, underwent apoptosis following delphinidin treatment. The possible explana-
tion to this process was shown as the inhibition of phosphatidylinositol 3,4,5-trisphosphate 
(PI3K)-dependent phosphorylation of AKT in vitro and inhibition of the activation of NF-κB 
in vivo [85]. The same study also pointed out that miR-27a and miR-155 were able to inhibit 
PI3K and NF-κB and responsible from the anti-inflammatory and cytotoxic activity of delph-
inidin in MDA-MB-231 breast cancer cell line [86]. Delphinidin has been also shown to inhibit 
hepatocyte growth factor (HGF)-mediated tyrosyl phosphorylation of focal adhesion kinase 
(FAK), Src, paxillin, Gab-1, and GRB-2, which are inducers of cell proliferation upon phos-
phorylation by growth factor signaling. Delphinidin, in the same study, was found to repress 
Ras-ERK MAPKs and PI3K/AKT/mTOR/p70S6K pathways [16]. The compound also has anti-
angiogenic and anti-invasive properties by decreasing MMP-9 activity in ER+ MCF-7 cells. 
Im et al. showed that delphinidin inhibited MMP-9 transcription by blocking NF-κB through 
MAPK signaling pathways [87].
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3.5.3. Pelargonidin
Pelargonidin, a subclass of anthocyanin with estrogenic activity, was tested in MCF-7 breast 
cancer cells. The cytotoxic dose (5 μg/ml) of strawberry extract containing pelargonidin-3-O-
glucoside caused 50% decrease in cell proliferation [88]. A study performed in breast cancer 
tissue of rats showed that pelargonidin could inhibit the synthesis of cytochrome c p450 family 
1 subfamily A member 1 (CYP1A1) enzyme which converts estradiol into 2-hydroxy-estradiol 
that can cause DNA damage [89]. The inhibition of the estrogenic activity by 55% was also 
indicated following pelargonidin containing pomegranate seed oil in ER+ MCF-7 cells. On the 
other hand, pelargonidin treatment induced apoptosis in both MCF-7 and MDA-MB-231 (ER-). 
Seventy-five percent inhibition of invasion across a Matrigel was also observed in MCF-7 cells 
at 10 μg/ml pomegranate seed oil concentration. Studies suggest that further investigations on 
chemopreventive and therapeutic applications of pelargonidin should be performed against 
human breast cancer [90].
3.6. Isoflavonoids
3.6.1. Daidzein
Daidzein, is one of the isoflavonoid present in various plants and herbs such as soybeans, 
tofu, kwao krua (Pueraria mirifica), kudzu (Pueraria lobata), and also isolated from Maackia 
amurensis cultures [91]. Breast tumor growth inhibition by lower concentration of daidzein 
(10 μM) treatment in in vitro and in vivo has been reported. Daidzein prevented T47D breast 
cancer cell proliferation and acted as antiestrogenic agent [92]. Fifty micrometer daidzein 
concentration decreased the cell viability in MDA-MB-231 and MCF-7 breast cancer cells by 
50 and 42%, respectively, for 48 h. Moreover, daidzein inhibited cell migration and invasion 
in breast cancer cells by using MicroRaman techniques [93]. As a soybean extract, daidzein 
stabilized proto-oncogene BRF2 mRNA and decreases BRF2 promoter methylation in ERα 
and ERβ breast cancer cells and female breast cancer mice models [94]. Antiproliferative 
effect of daidzein on breast cancer cells was reported by acting on TNF-α expression, down-
regulating MMP-9 mRNA expression, and suppressing hedgehog signaling through pre-
venting the Gli1 nuclear translocation. In in vivo MCF-7 athymic nude mice breast cancer 
models, fed daidzein prevented tumor growth through suppressing ATP2A3 and BLNK 
expression and decreased MYC oncogene expression [95]. However, no significant associa-
tion between breast cancer risk and plasma equol and/or equol: daidzein concentrations 
have been reported in the Chinese population [96].
3.6.2. Genistein
Soybean is one of the dietary components, which contains phytoestrogens and genistein act-
ing as a chemopreventive agent against various cancer cells such as prostate and breast cancer. 
As a predominant isoflavone, genistein inhibits growth and proliferation of ER-positive and 
ER-negative breast cancer cells by inhibiting receptor-associated tyrosine kinase (RTK) signal-
ing [97]. Genistein inhibited cell proliferation, growth, invasion, and metastasis and acted as 
anticarcinogenic and anti-angiogenic compound on breast cancer in vitro and in vivo models 
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[98]. The molecular mechanism of anticarcinogenic effect of genistein on breast cancer cells 
is due to DNA topoisomerase, 5-reductase enzyme inhibition, suppressing the NF-κB, Akt 
and MAPK signaling pathways [99]. Genistein is one of the flavonoids that has been shown 
to effect on chronic diseases such as atherosclerosis and hereditary hemorrhagic telangiec-
tasia. The molecular target of genistein was reported to enhance the action of transforming 
growth factor-β (TGF-β) [77]. Like other plant secondary metabolites (tocopherols, curcumin), 
flavonoids reported to regulate VEGF in breast tumors in vivo and in vitro studies. The anti-
angiogenic, anticarcinogenic effect of genistein target VEGF receptor-2 (VEGFR-2) medi-
ated PI3K/Akt/mTOR signaling pathway [100]. Angiogenesis is the formation of new blood 
vessels and sprouting of circulation by activation of VEGF family member, VEGF-A, lead-
ing to endothelial cell proliferation, migration, and destruction of matrix metalloproteins. 
Although the anti-angiogenic effect of isoflavonoids has been reported in various studies, the 
exact molecular inhibition mechanism has not been clarified yet. One of the anti-angiogenic 
effects of genistein is the inhibition of VEGF and its receptor secretion. Ten to fifty microm-
eter genistein prevented basal VEFG expression both in breast cancer and human umbili-
cal vein endothelial cells (HUVECs) [101]. Moreover, under hypoxia conditions genistein 
has been shown to induce both VEGF downregulation and inhibition of hypoxia-inducible 
factor 1 (HIF-1) activation. The anti-angiogenic effect of genistein has been accelerated with 
curcumin-combined treatment in HUVEC cells by VEGFR-1 and VEGFR-2 downregulation 
[102]. According to in vivo experiments such as xenografts, chick chorioallantoic membrane 
or zebra fish experimental models showed the reduction of microvessel density due to genis-
tein treatment mediated by plasminogen activator inhibitor-1, endostatin, angiostatin, and 
thrombospondin-1 activation. Pretreatment with genistein leads to the reduction of MMP-2, 
MMP-3, MMP-13, and MMP-15 mRNA expression and VEGF-mediated plasminogen activa-
tor (PA) and PAI1 expression blockage. However, no significant effect has been determined on 
MMP-2 and MMP-9 activity. Antiproliferative and anti-angiogenic effect of genistein is also 
shown by inhibition of cadherin, integrin V, connexin 43 mRNA expression, and genistein 
(40 mmol/L), or daidzein (110 μm/L) treatment suppresses epidermal growth factor (EGF) 
and insulin-like growth factor (IGF-I) [103]. NF-κB signaling pathway plays an important role 
in not only angiogenesis but also cell growth apoptosis, inflammation, and invasion. Thus, 
genistein treatment inhibited MMP-9 by NF-κB nuclear translocation-induced NF-κB signal-
ing inactivation [104]. In addition, genistein induced cell proliferation suppression by acting 
on MAPKs such as ERK-1/2, c-Jun N-terminal kinases (JNK), and p38 dephosphorylation. 
In order to clarify the anti-angiogenic effect of flavonoids, genistein, one of the major cata-
lytic enzymes of prostaglandin production [cyclooxygenase-2 COX-2], associated VEGF pro-
duction was investigated [105]. COX isoenzyme catalyzes the production of prostaglandins, 
VEGF production, and angiogenesis induction. In MCF-7 breast cancer cells, genistein alone 
or combined treatment with capsaicin leads anti-angiogenic and anticarcinogenic effect via 
acting on reduced COX-2 expression. According to in vivo studies, in TPA-treated animals, 
genistein or daidzein suppresses NF-κB and COX-2 activity [77]. During cancer progression, 
various molecules have been involved in various steps such as cell proliferation, differen-
tiation, migration, and extracellular matrix formation. Moreover, some tumor microenvi-
ronment modulators such as immunosuppressive and/or angiogenic-inducing factors play 
essential roles. One of the key targets during these hypoxic breast tumors is galectin-3 that 
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is involved by overexpression in cancer niche. Soy compound isoflavonoid genistein chemo-
preventive effect has been reported due to potential action on galectin-3 expression inhibition 
in breast cancer. The phytoestrogen genistein, which induced G2/M arrest due to galentin-3 
downregulation, has been determined in human breast carcinoma cell lines [106]. As shown 
in Figure 3, analysis of transcriptomic profile of mammary epithelial cells of rat females fed a 
diet containing the soy isoflavone genistein or soy protein isolate showed that soy consump-
tion is associated with reduced breast cancer risk in women. Results provide insight into the 
molecular basis of the beneficial effect of soy-rich diets.
 Figure 3. GEO Dataset (GDS2616) demonstration for soy protein genistein protective effect against mammary epithelial 
cells in Rattus norvegicus.
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4. Conclusion
In summary, flavonoids can potentially contribute to breast cancer prevention and treatment 
either by antioxidant or apoptotic activity (Table 1). Previous studies highlighted that plant-
derived flavonoids are promising when their bioavailability is increased to provide better 
therapeutic approach in the treatment of disease. However, elucidation of their molecular tar-
gets in cell type-specific manner may increase their potential therapeutic effects. Noteworthy 
that consumption of dietary flavonoids in diet types might be advised to control disease and 
poor prognosis.
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The effect caused by flavonoid treatment in breast cancer models
Group of flavonoid Subgroup Apoptotic Anti-angiogenic Antioxidant
Flavanols Quercetin + +
Kaempferol + + +
Myricetin +
Isorhamnetin + +
Silymarin + +
Flavanes Luteolin + +
Apigenin + +
Flavanones Naringenin +
Eriodictyol +
Hesperetin +
Flavan-3-ols Cyanidin + + +
Delphinidin +
Pelargonidin +
Isoflavonoids Daidzein +
Genistein + +
Table 1. The summary of the effects of flavonoids in breast cancer.
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